Navigation Links
Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
Date:6/28/2010

ARDEE, Ireland, June 28 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that it has received a Paragraph IV Certification Notice from Par Pharmaceutical, Inc. ("Par").  The Paragraph IV Certification Notice advises the Company of the filing of an Abbreviated New Drug Application (ANDA) by Par for a generic version of the Company's ASACOL 400 mg delayed release mesalamine product.

ASACOL 400 mg, which the Company markets and sells in the United States under a license from Medeva Pharma Suisse AG ("Medeva"), is used in the treatment of ulcerative colitis and is protected by Medeva's U.S. Patent Nos. 5,541,170 and 5,541,171, each of which expire in July 2013.

The Company is currently reviewing the details of the Paragraph IV Certification Notice from Par and continues to have full confidence in the intellectual property protecting its ASACOL 400 mg product.

The Company

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the North American and Western European pharmaceuticals markets.  The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products.  WCRX-F

Forward-Looking Statements

This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.

The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation, including domestic and foreign health care reform, affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; our ability to realize the anticipated opportunities from our acquisition of the global branded prescription pharmaceuticals business of The Procter & Gamble Company; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2009, and from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.


'/>"/>
SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent
2. Dr. Mahdi B. Fawzi Joins Warner Chilcott as President, Global Research and Development
3. Warner Chilcott Completes Acquisition of P&Gs Global Branded Prescription Pharmaceuticals Business
4. Warner Chilcott Announces 2010 Financial Guidance Conference Call
5. Warner Chilcott Announces Secondary Equity Offering
6. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
7. Warner Chilcott Prices Secondary Equity Offering
8. Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015
9. Warner Chilcott Considers Potential Repurchase or Redemption of 8.75% Senior Subordinated Notes
10. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2010 Financial Results
11. Warner Chilcott to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/16/2017)... Corp. is voluntarily performing a worldwide field correction of certain Intra-Aortic Balloon Pumps ... ... CS100i IABP ... 0998-UC-0446HXX; 0998-UC-0479HXX 0998-00-3013-XX;  0998-UC-3013-XX 0998-00-3023-XX;  0998-UC-3023-XX ... This field correction also applies to any System 98 or ...
(Date:6/14/2017)... N.C. , June 14, 2017  In 2016, ... Creative Startups pitch competition and came away ... reality platform is described by Forbes as "entering the ... American Medical Association as teaching "empathy to medical professionals ... the startup was recently named a finalist for the ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is ... for excellence as a Podiatrist in Alabama . ... at Family First Foot Care. He brings over 20 years of ... pain management and healthcare, to his role. ... Foot Care, PC is pleased to welcome you to ...
Breaking Medicine Technology:
(Date:6/27/2017)... Fla. (PRWEB) , ... June 27, 2017 , ... ... today announced the appointment of Mike Finnegan to the position of Executive Vice ... years of experience in healthcare technology, telehealth and medical device sales leadership. He ...
(Date:6/27/2017)... ... ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation Act ... Affordable Care Act (ACA), would result in 22 million Americans losing their health insurance ... than 20 million Americans have gained health insurance under the ACA, and from 2013 ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... and personal financial planning services to residents of southern New Hampshire, is teaming ... that promises to fight hunger and homelessness in the region. , New Horizons ...
(Date:6/27/2017)... ... 2017 , ... Hammer Strength, the world’s leading performance strength training brand, and ... Houston Rockets the NBSCA Strength & Conditioning Coach of the Year. , In ... vote to select the coach who embodies the highest level of excellence and outstanding ...
(Date:6/26/2017)... ... June 26, 2017 , ... Torrance dentist, Dr. Robert Mondavi ... of the most noticeable aspects of a person’s appearance. A healthy, radiant smile can ... with beautiful, balanced teeth, everyone can have the smile of their dreams with cosmetic ...
Breaking Medicine News(10 mins):